Identification of a Potentially Functional circRNA-miRNA-mRNA Regulatory Network in Melanocytes for Investigating Pathogenesis of Vitiligo

Lili Li*, Zhi Xie, Xiliang Qian, Tai Wang, Minmin Jiang, Jinglin Qin, Chen Wang, Rongqun Wu and Canling Song

Department of Dermatology, People’s Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

CircRNAs have been reported to play essential roles in regulating immunity and inflammation, which may be an important regulatory factor in the development of vitiligo. However, the expression profile of circRNAs and their potential biological functions in vitiligo have not been reported so far. In our study we found there are 64 dysregulated circRNAs and 14 dysregulated miRNAs in the patients with vitiligo. Through the correlation analysis, we obtained 12 dysregulated circRNAs and 5 dysregulated miRNAs, forming 48 relationships in the circRNA-miRNA-mRNA regulatory network. Gene Ontology analysis indicated dysregulated circRNAs in vitiligo is closely related to the disorder of the metabolic pathway. The KEGG pathway of dysregulation of circRNAs mainly enriched in the biological processes such as ubiquitin mediated proteolysis, endocytosis and RNA degradation, and in Jak-STAT signaling pathway. Therefore, we found the circRNA-miRNA-mRNA regulatory network are involved in the regulation of numerous melanocyte functions, and these dysregulated circRNAs may closely related to the melanocyte metabolism. Our study provides a theoretical basis for studying the vitiligo pathogenesis from the perspective of circRNA-miRNA-mRNA network.

Keywords: vitiligo, circRNAs, ceRNA, metabolism, melanocyte

INTRODUCTION

Vitiligo is characterized by the progressive disappearance of melanocytes, resulting in depigmentation of the skin and/or hair (Malhotra and Dytoc, 2013). The exact pathogenesis remains unknown. Several hypotheses about the pathogenesis mechanisms have been implicated, including genetic, autoimmune, biochemical factors, oxidative stress, and neural or viral causes (Iannella et al., 2016).

Circular RNAs (circRNAs) are a type of covalently closed, single-stranded circular non-coding RNA (Chen and Yang, 2015). Accumulating evidence has shown that circRNAs are widespread and diverse throughout eukaryotic cells and that they have multiple biological functions and play potentially important roles in various diseases (Lei et al., 2018). CircRNAs play an important role...
in regulating cell proliferation, inflammation and immunity (Chen et al., 2019b; Liu et al., 2019). Therefore, circRNAs are considered to be an important regulator of the onset and development of vitiligo and may be a new therapeutic target for vitiligo.

Circular RNAs are rich in miRNA binding sites (miRNA response elements, MREs), serving as miRNA sponges or competitive endogenous RNAs (ceRNAs). CircRNA regulates mRNA at the post-transcriptional level by completely binding to shared miRNAs (Kristensen et al., 2019). However, circRNAs as ceRNAs mediating pathological processes has not been reported in vitiligo.

Studies on circRNA regulation in vitiligo are limited, the expression profile of circRNAs and their potential biological functions in vitiligo have not been reported so far. In our study, we used RNA-seq to investigated comprehensive circRNA expression profile between vitiligo lesions and normal healthy skin tissue, further to explore the possible regulated mechanism of circRNAs in the pathogenesis of vitiligo.

MATERIALS AND METHODS

Patients and Tissue Specimens

Fresh tissues were obtained from patients with vitiligo and normal donors, from April 2019 to April 2020. The study was approved by the committee of People’s Hospital of Guangxi Zhuang Autonomous Region and all subjects signed an informed consent form under the code KY-ZGR-2019-013. This study included a total of 6 adult patients and 6 control subjects, male and female adults between the ages of 30–60. The patients with vitiligo were diagnosed with vitiligo vulgaris, defined as a condition with depigmentation between 10% and 80% of the body surface. The detail information was shown in Supplementary Table 1.

Skin tissue obtained by skin punch biopsy (4 mm diameter) of the normal areas from normal donors and the lesions from vitiligo patients. Two skin biopsies were obtained from each patient with vitiligo and control subjects. The biopsy was obtained from the central part of the affected skin from patients with vitiligo. Control skin biopsy was taken from healthy control subjects at the same part vs. patient with vitiligo.

RNA Extraction and Qualification?

Total RNA was extracted from each skin biopsies by RNAprep Pure Tissue Kit (TIANGEN BIOTECH, Beijing, China) in accordance with the manufacturer’s instructions.

We monitored RNA degradation and contamination used 1% agarose gels. And using the NanoPhotometer® spectrophotometer (IMPLEN, CA, United States) to check RNA purity. Then we measured RNA concentration by Qubit® RNA Assay Kit in Qubit® 2.0 Fluorometer (Life Technologies, CA, United States) and assessed RNA integrity by the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, CA, United States).

RNA-Seq

Details of the circRNA-seq and miRNA-seq methods are described in Supplementary Materials. Briefly describe as that:

CircRNA-Seq

A total amount of 3 µg RNA per sample was used as input material for the RNA sample preparations. Sequencing libraries were generated using NEBNext® UltraTM RNA Library Prep Kit for Illumina® (NEB, United States) following manufacturer’s recommendations and index codes were added to attribute sequences to each sample. Briefly, mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. In order to select cDNA fragments of preferentially 150~200 bp in length, the library fragments were purified with AMPure XP system (Beckman Coulter, Beverly, United States). Then 3 µl USER Enzyme (NEB, United States) was used with size-selected, adaptor-ligated cDNA at 37°C for 15 min followed by 5 min at 95°C before PCR. Then PCR was performed with Phusion High-Fidelity DNA polymerase, Universal PCR primers and Index (X) Primer. At last, PCR products were purified (AMPure XP system) and library quality was assessed on the Agilent Bioanalyzer 2100 system. The clustering of the index-coded samples was performed on a cBot Cluster Generation System using TruSeq PE Cluster Kit v3-cBot-HS (Illumia) according to the manufacturer’s instructions. After cluster generation, the library preparations were sequenced on an Illumina Hiseq platform and 125 bp/150 bp paired-end reads were generated. Index of the reference genome was built using STAR and paired-end clean reads were aligned to the reference genome using STAR (v2.5.1b). The circRNA were detected and identified using find_circ and CIRI2 (Memczak et al., 2013; Gao et al., 2018). HTSeq v0.6.0 was used to count the reads numbers mapped to each gene. Differential expression analysis of two conditions/groups (two biological replicates per condition) was performed using the DESeq2 R package (1.10.1). Genes with an adjusted P-value < 0.05 found by DESeq2 were assigned as differentially expressed.

MiRNA-Seq

A total amount of 3 µg total RNA per sample was used as input material for the small RNA library. Sequencing libraries were generated using NEBNext® Multiplex Small RNA Library Prep Set for Illumina® (NEB, United States) following manufacturer’s recommendations and index codes were added to attribute sequences to each sample. Library quality was assessed on the Agilent Bioanalyzer 2100 system using DNA High Sensitivity Chips. The clustering of the index-coded samples was performed on a cBot Cluster Generation System using TruSeq SR Cluster Kit v3-cBot-HS (Illumia) according to the manufacturer’s instructions. After cluster generation, the library preparations were sequenced on an Illumina Hiseq 2500/2000 platform and 50 bp single-end reads were generated. The small RNA tags were mapped to reference sequence by Bowtie without mismatch to analyze their expression and distribution on the reference (Langmead et al., 2009). mirBase20.0 was used as reference, modified software mirdeep2 and srna-tools-cli were used to obtain the
potential miRNA and draw the secondary structures. To remove tags originating from protein-coding genes, repeat sequences, rRNA, tRNA, snRNA, and snoRNA, small RNA tags were mapped to RepeatMasker, Rfam database or those types of data from the specified species itself. The characteristics of hairpin structure of miRNA precursor can be used to predict novel miRNA. The available software miREvo and mirdeep2 were integrated to predict novel miRNA through exploring the secondary structure, the Dicer cleavage site and the minimum free energy of the small RNA tags unannotated in the former steps. miRNA expression levels were estimated by TPM (transcript per million) through the following criteria: Normalization formula: Normalized expression = mapped readcount/Total reads*1000000. Differential expression analysis of two conditions/groups was performed using the DESeq R package (1.8.3). The P-values was adjusted using the Benjamini

**FIGURE 1 | Expression Profiles of dysregulated circRNAs and miRNAs.** (A) Volcanoplot of circRNAs. Green, red, and blue points represent circRNAs that were downregulated, upregulated, and not significantly different in vitiligo relative to normal control. (B) Cluster analysis of expression of circRNAs. Red represent increased expression, blue represent decreased expression. (C) Volcanoplot of miRNAs. Green, red and blue points represent miRNAs that were downregulated, upregulated, and not significantly different in vitiligo relative to normal control. (D) Cluster analysis of expression of miRNAs. Red represent increased expression, blue represent decreased expression.
TABLE 1 | Differently expressed circRNAs in RNA-seq.

**Up-regulated**

| Name           | p-value     | log2FoldChange | circRNA type | Chr. | Source gene name |
|----------------|-------------|----------------|--------------|------|-----------------|
| hsa_circ_0003164 | 0.0020969   | 5.4848         | Exon         | 14   | ZC3H14          |
| hsa_circ_0004276 | 0.0025305   | 5.578          | Exon         | 3    | SUCLG2          |
| hsa_circ_0004293 | 0.003171    | 5.221          | Exon         | 11   | DDX6            |
| hsa_circ_0005483 | 0.0069774   | 4.9833         | Exon         | 16   | LMF1            |
| novel_circ_0004933 | 0.010811   | 4.8029         | Exon         | 4    | GUCY1A1         |
| hsa_circ_0008558 | 0.0111      | 4.7886         | Exon         | 16   | LONP2           |
| hsa_circ_0007716 | 0.011469    | 4.7377         | Exon         | 17   | WSB1            |
| hsa_circ_0007803 | 0.012342    | 4.7311         | Exon         | 1    | LZIC            |
| hsa_circ_0001833 | 0.017868    | 4.533          | Exon         | 8    | MROH1           |
| novel_circ_0002817 | 0.022658   | 4.3978         | Exon         | 1    | TNN             |
| hsa_circ_0003770 | 0.025343    | 4.3334         | Exon         | 12   | AC073610.2;ARF3 |
| hsa_circ_0004306 | 0.028855    | 4.25            | Exon         | 3    | SUCLG2          |
| hsa_circ_00083265 | 0.028879   | 4.25            | Exon         | 8    | AO019257.8;ARHGEF10 |
| novel_circ_0001719 | 0.029043    | 4.249          | Exon         | 15   | IQGAP1          |
| hsa_circ_0001377 | 0.029173    | 4.2479         | Exon         | 3    | TNK2            |
| hsa_circ_0005133 | 0.029589    | 4.2381         | Exon         | 6    | DDR1            |
| hsa_circ_0004888 | 0.031266    | 4.2048         | Exon         | 2    | PPIG            |
| novel_circ_0000333 | 0.036126   | 4.1166         | Exon         | 10   | SHOC2           |
| novel_circ_0001995 | 0.036814    | 4.0813         | Intron       | 17   | PAFAH1B1        |
| novel_circ_0004175 | 0.038492    | 4.0731         | Exon         | 2    | XP1             |
| novel_circ_0002133 | 0.038996    | 4.0627         | Exon         | 17   | MBTD1           |
| hsa_circ_0002274 | 0.038149    | 4.0575         | Exon         | 1    | LPGAT1          |
| novel_circ_0001407 | 0.040647    | 4.0352         | Exon         | 14   | FOXN3           |
| novel_circ_0004223 | 0.043796    | 3.9864         | Exon         | 2    | EXOC6B          |
| hsa_circ_0006979 | 0.044747    | 3.9757         | Exon         | 16   | RSL1D1          |
| novel_circ_0001137 | 0.044747    | 3.9757         | Exon         | 13   | SETDB2          |
| hsa_circ_0002215 | 0.044973    | 3.9668         | Intron       | 10   | CAMK1D          |
| hsa_circ_00568838 | 0.044973   | 3.9668         | Exon         | 2    | 7-Mar           |
| hsa_circ_0008378 | 0.045624    | 3.9572         | Exon         | 15   | PIAS1           |
| hsa_circ_0001699 | 0.045942    | 3.9522         | Exon         | 7    | CDK13           |
| hsa_circ_0030716 | 0.046266    | 3.9423         | Exon         | 13   | DOCK9           |
| hsa_circ_0001621 | 0.049329    | 3.9029         | Exon         | 6    | CASP8AP2        |
| hsa_circ_0008458 | 0.049329    | 3.9029         | Exon         | 20   | TCFL5           |
| novel_circ_0004181 | 0.049329    | 3.9029         | Exon         | 2    | EBP1            |

**Down-regulated**

| ID             | p-value     | log2FoldChange | circRNA type | Chr. | Source gene name |
|----------------|-------------|----------------|--------------|------|-----------------|
| novel_circ_0006548 | 0.0086321   | −4.8793        | Exon         | 9    | NIPSNAP3A       |
| hsa_circ_0001789 | 0.016851    | −4.5361        | Exon         | 8    | RAB11FIP1       |
| hsa_circ_0012300 | 0.016611    | −4.5127        | Exon         | 1    | PK3R3;AL358075.4 |
| hsa_circ_0087961 | 0.020012    | −4.4137        | Intron       | 9    | LPAR1           |
| hsa_circ_0004771 | 0.019942    | −4.4127        | Exon         | 21   | NIP1            |
| hsa_circ_0003572 | 0.020147    | −4.4092        | Exon         | 1    | COP1            |
| hsa_circ_0002762 | 0.021366    | −4.3784        | Exon         | 12   | CDK17           |
| hsa_circ_0007683 | 0.022732    | −4.3418        | Exon         | 1    | ER3             |
| hsa_circ_0001523 | 0.025985    | −4.2617        | Exon         | 5    | ZNF608          |
| hsa_circ_0013252 | 0.028224    | −4.2383        | Exon         | 1    | PTBP2           |
| hsa_circ_0023812 | 0.028701    | −4.2025        | Exon         | 11   | NARS2           |

(Continued)
TABLE 1 | Continued

| ID               | p-value  | log2FoldChange | circRNA type | Chr. | Source gene name |
|------------------|----------|----------------|--------------|------|------------------|
| hsa_circ_0077216 | 0.030247 | −4.1728        | Exon         | 6    | ME1              |
| hsa_circ_0054877 | 0.030205 | −4.1723        | Exon         | 2    | XPO1             |
| hsa_circ_0091669 | 0.031859 | −4.1681        | Exon         | 3    | X                |
| hsa_circ_0067985 | 0.030721 | −4.1637        | Exon         | 8    | HAS2             |
| hsa_circ_0039353 | 0.033533 | −4.1326        | Exon         | 16   | CHD9             |
| hsa_circ_0019006 | 0.034523 | −4.0928        | Exon         | 10   | WAPL             |
| novel_circ_0005288 | 0.037215 | −4.0444       | Exon         | 3    | SMARCC1          |
| hsa_circ_0003602 | 0.040379 | −3.9934        | Exon         | 8    | ASAP1            |
| hsa_circ_0085616 | 0.042635 | −3.9764        | Exon         | 4    | SNX25            |
| hsa_circ_0004874 | 0.041586 | −3.9729        | Exon         | 6    | CASP8AP2         |
| novel_circ_0005877 | 0.041578 | −3.9717       | Exon         | 3    | CNOT10           |
| novel_circ_0004624 | 0.044765 | −3.9235        | Exon         | 10   | ATRNL1           |
| hsa_circ_0020093 | 0.04839  | −3.8923        | Exon         | 12   | BAZ2A            |
| hsa_circ_0035649 | 0.047265 | −3.8877        | Exon         | 12   | RNF10            |
| hsa_circ_0004843 | 0.048858 | −3.8841        | Exon         | 4    | SEC31A           |
| hsa_circ_0028899 | 0.023216 | −2.9137        | Exon         | 5    | HMGCS1           |
| hsa_circ_0003549 | 0.03858  | −2.8558        | Exon         |      |                  |
| hsa_circ_0072391 | 0.043716 | −1.9864        | Exon         |      |                  |

and Hochberg method. Corrected P-value of 0.05 was set as the threshold for significantly differential expression by default.

Real-Time qPCR
To validate the RNA-Seq data, we randomly selected 2 of circRNA and 2 of miRNA for qRT-PCR analysis. Total RNA was extracted from each skin tissue sample, and then reverse-transcribed into cDNA using PrimeScript™ RT reagent Kit with gDNA Eraser (Takara, Dalian, China) according to the manufacturer’s instruction.

Quantitative PCR (qPCR) was performed using the SYBR® Premix Ex Taq™ II (Tli RNase H Plus) Kit with a Bio-Rad CFX Manager 3.1 real-time PCR system (CFX96™ Real-Time PCR, Bio-Rad, United States). The circRNA expression were normalized to GAPDH as an endogenous reference transcript, the miRNA expression were normalized to that of U6 (Zhong et al., 2019). The relative expression levels of circRNA and miRNA were calculated using the 2−ΔΔCt method. The specific primers for each gene are listed in Supplementary Table 2. Data shown represent the means of 3 experiments.

GO Annotations and KEGG Pathway Analyses
Gene Ontology (GO) enrichment analysis of differentially expressed genes was implemented by the clusterProfiler R package, in which gene length bias was corrected. GO terms with corrected P-value less than 0.05 were considered significantly enriched by differential expressed genes.

KEGG is a database resource for understanding high-level functions and utilities of the biological system, such as the cell, the organism and the ecosystem, from molecular-level information, especially large-scale molecular datasets generated by genome sequencing and other high-throughput put experimental technologies1. We used clusterProfiler R package to test the statistical enrichment of differential expression genes in KEGG pathways.

1http://www.genome.jp/kegg/

TABLE 2 | Differently expressed miRNAs in RNA-seq.

| Name              | p-value  | log2FoldChange |
|-------------------|----------|----------------|
| up-regulated      |          |                |
| has-miR-30e-3p     | 0.0030918| 1.198          |
| has-miR-27a-3p     | 0.0005853| 1.1978         |
| has-miR-24-1-5p    | 0.0001943| 1.109          |
| has-miR-218-5p     | 0.0006676| 1.0703         |
| has-miR-202b-5p    | 0.0034802| 0.8942         |
| has-miR-203a-3p    | 0.0034927| 0.89393        |

| Name              | p-value  | log2FoldChange |
|-------------------|----------|----------------|
| down-regulated    |          |                |
| has-miR-365a-3p    | 5.19E-09 | −2.038         |
| has-miR-369a-3p    | 9.26E-05 | −1.7424        |
| has-miR-197-3p     | 5.03E-09 | −1.6981        |
| has-let-7d-3p      | 0.0004904| −1.315         |
| has-miR-145-5p     | 0.00023207| −1.2295       |
| has-miR-127-3p     | 0.0010081| −1.1407        |
| has-miR-149-5p     | 0.0035472| −1.0741        |
| has-miR-320a-3p    | 0.0019116| −1.0613        |
FIGURE 2 | Identification of circRNA and miRNA expression by qPCR. circRNA expression was quantified relative to Gapdh expression level. miRNA expression was quantified relative to U6 expression level. Data are presented as means ± SD (n = 3; *p < 0.05).

FIGURE 3 | GO Enrichment Annotations of pathological progression of vitiligo. Significantly enriched GO pathways featured p values < 0.05.
Annotation for circRNA-miRNA-mRNA Interaction
Predicting circRNA-miRNA interactions and the target gene of miRNA were performed by TargetScan\(^3\) and miRanda\(^4\). Upregulation and downregulation of circRNA and miRNA were identified. Then, the circRNA-ceRNA regulatory networks were constructed through the Cytoscape software V2.7.0 (San Diego, CA, United States).

Statistical Analysis
Statistical analyses were performed using SPSS v16.0 software (SPSS, Inc., Chicago, IL, United States). All data were expressed as the mean ± SEM. \( p < 0.05 \) was statistically significant.

RESULTS
Overview of circRNA-Seq Data
A total of 583,336,760 raw reads were generated, 298,292,356 for patients with vitiligo, and 285,044,404 for control subjects. After poly(N)-containing, low-quality, and adaptor-containing reads were removed from the raw data, 572,982,714 clean reads remained: 293,183,756 for patients and 279,798,958 for control subjects. The clean reads were mapped to the available reference sequence using Hisat2\(^5\) (Pertea et al., 2016). circRNAs were identified and identified using find_circ and CIRI, 3,633 circRNAs were detected (Memczak et al., 2013; Gao et al., 2015). These circRNAs were used for subsequent analyses.

Overview of miRNA-Seq Data
A total of 71,225,504 raw reads were generated, 35,549,729 for patients with vitiligo, and 35,675,775 for control subjects. The clean reads were mapped to the available reference sequence using Hisat2\(^5\) (Pertea et al., 2016). CircRNAs were used for subsequent analyses.

Differential Expression of circRNAs and miRNAs in Vitiligo Patients and Control Subjects
We identified 64 significantly dysregulated circRNA transcripts between the two groups in skin tissue of subjects: 34 circRNAs were upregulated and 30 were downregulated in vitiligo patients relative to the control subjects, respectively (Figure 1A and Table 1). We conducted the cluster analysis of the circRNAs expression, and the heatmap results were shown in Figure 1B.

We obtained 14 significantly dysregulated miRNAs: inducing 6 miRNAs were upregulated and 8 were downregulated in skin tissue of vitiligo patients relative to the control subjects (Figure 1C and Table 2). We conducted the cluster analysis of the miRNAs expression, and the heatmap results were shown in Figure 1D.

The data showed that these differentially expressed circRNAs were scattered different chromosomes: 34 upregulated circRNAs and 30 downregulated circRNAs are presented in Table 1 and 2.

| CircRNA name | MiRNA name | Gene_id | Gene_name |
|--------------|------------|---------|-----------|
| hsa_circ_0007716 | hsa-miR-149-5p | ENSG00000138848 | DAB2IP |
| hsa_circ_0001377 | hsa-miR-149-5p | ENSG00000138848 | DAB2IP |
| hsa_circ_0030716 | hsa-miR-149-5p | ENSG00000138848 | DAB2IP |
| hsa_circ_0007716 | hsa-miR-149-5p | ENSG0000187764 | SEMA4D |
| hsa_circ_0001377 | hsa-miR-149-5p | ENSG0000187764 | SEMA4D |
| novel_circ_0001407 | hsa-miR-149-5p | ENSG0000187764 | SEMA4D |
| hsa_circ_0030716 | hsa-miR-149-5p | ENSG0000187764 | SEMA4D |
| hsa_circ_0003770 | hsa-miR-320a-3p | ENSG0000137747 | TMRSS13 |
| hsa_circ_0000215 | hsa-miR-320a-3p | ENSG0000137747 | TMRSS13 |
| novel_circ_0002133 | hsa-miR-145-5p | ENSG0000356664 | DAPK2 |
| hsa_circ_0004888 | hsa-miR-197-3p | ENSG0000116251 | RPL22 |
| hsa_circ_00056888 | hsa-miR-197-3p | ENSG0000116251 | RPL22 |
| hsa_circ_0001621 | hsa-miR-197-3p | ENSG0000116251 | RPL22 |
| hsa_circ_0007716 | hsa-miR-197-3p | ENSG0000148179 | C11orf49 |
| hsa_circ_0001377 | hsa-miR-197-3p | ENSG0000148179 | C11orf49 |
| novel_circ_0001407 | hsa-miR-197-3p | ENSG0000148179 | C11orf49 |
| hsa_circ_0030716 | hsa-miR-197-3p | ENSG0000089060 | SLCO8B1 |
| hsa_circ_0003770 | hsa-miR-197-3p | ENSG0000089060 | SLCO8B1 |
| hsa_circ_0000215 | hsa-miR-320a-3p | ENSG0000137747 | TMRSS13 |

\(^2\)http://www.targetscan.org
\(^3\)http://www.microrna
\(^4\)http://ccb.jhu.edu/software/hasit2
location in 16 chromosomes, and 30 downregulated circRNAs location in 14 chromosomes. The top chromosomes for the upregulated circRNAs were chr. 2 (6/34), while the top two chromosomes for the downregulated circRNAs were chr. 1 (4/30). The localization of these differentially expressed circRNAs included 32 exonic and 2 intronic in the upregulated circRNAs, and 29 exonic and 1 intronic in the downregulated circRNAs (shown in Table 1).

**Confirmation the Differential Expression of circRNAs and miRNAs**

We sought to confirm the differential expression identified in our RNA-seq experiments using qPCR. The differentially expressed transcripts of circRNAs and miRNAs were randomly selected. As shown in Figure 2, all selected transcripts were detected in skin tissue of vitiligo patients and the control subjects and exhibited significant differential expressions. The expression of hsa_circ_0003164 was 1.29 ± 0.068 in patients with vitiligo vs. 0.86 ± 0.131 in control subjects (p < 0.05). The expression of hsa_circ_0028899 was 0.82 ± 0.282 in patients with vitiligo vs. 1.35 ± 0.305 in control subjects (p < 0.05). The expression of hsa-miR-30e-3p was 2.62 ± 0.612 in patients with vitiligo vs. 1.52 ± 0.421 in control subjects (p < 0.05). The expression of hsa-miR-203b-5p was 3.23 ± 0.673 in patients with vitiligo vs. 1.70 ± 0.409 in control subjects (p < 0.05). In summary, our qPCR validation study confirmed the profiles revealed by the RNA-seq data, thus indicating the reliability of the sequencing data.

**Go and KEGG Analyses for the Differential Expressed circRNAs**

We performed GO analyses on these dysregulated circRNAs in the networks and the results of the top highly enriched GO terms of cellular component (CC), biological process (BP), and molecular function (MF) are shown in Figure 3. The top terms were molecular function (GO:0003674), cellular process (GO:0009987), and cell (GO:0005623). Several metabolism-associated terms were also observed, such as metabolic process (GO:0008152), organic substance metabolic process (GO:0071704), cellular metabolic process (GO:0044237), regulation of biological process (GO:0050789), cellular macromolecule metabolic process (GO:0044260),

![Statistics of Pathway Enrichment](image_url)

**FIGURE 4 |** KEGG analysis of circRNA-associated ceRNA network in vitiligo pathology. Significantly enriched KEGG pathways featured p values < 0.05.
and regulation of metabolic process (GO:0019222). Thus, we hypothesize that the pathogenesis of vitiligo may be closely related to many metabolic-related pathways regulated by circRNAs.

We further conducted KEGG pathway analysis to determine the signaling cascades related to dysregulated circRNAs by using the Q-value scale from 0 to 1, and the top 5 significantly enriched pathways were identified: synthesis and degradation of ketone bodies, terpenoid backbone biosynthesis, butanoate metabolism, propanoate metabolism, and citrate cycle (TCA cycle) (Figure 4).

Construction of a circRNA-miRNA-mRNA Regulatory Network

According to ceRNA hypothesis, RNA transcripts effectively communicate with one another. The members of ceRNA compete for the same miRNA response elements (MREs) to regulate one another. We have conducted the regulatory network analysis of circRNA, miRNA, and their target genes. These data show that there are significant differential expression between vitiligo patients and the control subjects (corrected \( p < 0.05 \)). Analysis based on the RNA-seq data, we selected 12 circRNAs and 5 miRNAs that were differentially expressed, containing 48 relationships in the circRNA-miRNA-mRNA regulatory network (Figure 5A and Table 3).

The ceRNA network covered two cases: one was circRNA (upregulated in vitiligo)-miRNA (downregulated in vitiligo)-mRNA (upregulated in vitiligo), and the other one was circRNA (downregulated)-miRNA (upregulated)-mRNA (upregulated). Among them, there are 46 relationships in the manner of up-down-up, occupying the leading position, and only 2 relationships in the manner of down-up-down.

These RNA interactions may supply a novel perspective for the pathogenesis of vitiligo. We observed that one miRNA could be regulated by multiple circRNAs, further regulated a variety of downstream genes that are closely related to melanocyte proliferation or melanin synthesis, such as SEMA4D (ENSG00000187764), RPL22 (ENSG00000116251), ATG13 (ENSG00000175224), and ANKRD6 (ENSG00000135299). For example, hsa-miR-149-5p was co-related with hsa_circ_0007716, novel_circ_0001407, hsa_circ_0030716 and hsa_circ_0001377, further to regulate SEMA4D, ATG13, and ANKRD6.

Moreover, it has been reported that ATG13, SEMA4D, SMAD3, and Paxillin are closely related to the function of melanocytes. Therefore, the circRNA-ceRNA networks that regulate these genes may play important roles in regulating the physiology and pathology of vitiligo. These circRNA-ceRNA networks include: hsa_circ_0007716/novel_circ_0001407/hsa_circ_0030716/hsa_circ_0001377 – hsa-miR–149–5p – ENSG00000175224 (ATG13)/ENSG00000187764 (SEMA4D), hsa_circ_0003770/hsa_circ_0000215 – hsa-miR-320-3p – ENSG00000166949 (SMAD3), hsa_circ_0020093/hsa_circ_0087961 – hsa-miR-27a-3p – ENSG00000089159 (PAXILLIN).

The more significant differential expression of circRNA, the more likely it has an important role in the regulatory network. Therefore, we obtained the circRNA-ceRNA networks that might have the important roles in vitiligo pathology: hsa_circ_0007716 – hsa-miR-149-5p – ATG13/SEMA4D, hsa_circ_0030716 – hsa-miR-320a-3p – SMAD3 and hsa_circ_0087961 – hsa-miR-27a-3p – PAXILLIN.

Furthermore, we detected the expression of target genes such ANKRD6, ATG13, SEMA4D, SMAD3, and PAXILLIN to verify that these circRNA-ceRNA networks are involved
in the pathological process of vitiligo. As the results shown that the expression of ANKR6, ATG13, SEMA4D, SMAD3, and PAXILLIN were all significantly downregulated in vitiligo (Figure 5B). And, only the expression change of PAXILLIN conforms to the profile of circRNA-miRNA-mRNA. Therefore, we hypothesize that circ_0087961-miR-27a-3p-PAXILLIN might play an important regulatory role in the pathology of vitiligo.

**DISCUSSION**

Vitiligo is a common chronic acquired disease of pigmentation. Recent clinical and experimental studies suggest that the main mechanism leading to vitiligo involves in autoimmune dysfunction, neurotoxic factor destruction, oxidative stress and genetic factors (Iannella et al., 2016). These factors further lead to loss of melanocyte adhesion and destruction of melanocytes, thereby causing pigmentation loss (Speeckaert and van Geel, 2017; Delmas and Larue, 2019). Vitiligo is a complex genetic disease. Fifty genes at least have already been evaluated in order to identify a link with vitiligo (Sharma et al., 2017; Yuan et al., 2019). Recent studies have suggested that the occurrence and progression of vitiligo are due to multiple factors and gene interactions in which non-coding RNAs contribute to an individual’s susceptibility to vitiligo (Mansuri et al., 2016; Vaish et al., 2019).

CircRNAs are non-coding RNAs characterized by a unique covalent closed-loop structure. It is widely known that circRNAs are rich in miRNA binding sites (miRNA response elements, MREs), serving as miRNA sponges or competitive endogenous RNAs (ceRNAs), which leading the inhibitory effect of miRNAs on their target genes and further increased expression of the target genes (Salzmann, 2016; Kristensen et al., 2019). In this mechanism the circRNAs acting as miRNA sponges, play an important role in the regulation of diseases via their interaction with disease-associated miRNAs.

In our study we found there are 64 dysregulated circRNAs in the patients with vitiligo, including 34 circRNAs were upregulated and 30 were downregulated. And also there are 14 dysregulated miRNAs identified in vitiligo, 6 miRNAs were upregulated and 8 were downregulated. Through the correlation analysis, we obtained 12 dysregulated circRNAs and 5 dysregulated miRNAs, forming 48 relationships in the circRNA-miRNA-mRNA regulatory network. Our results showed that 12 dysregulated circRNAs had miRNAs binding sites, and were thus predicted to play a regulatory role via the ceRNA mechanism. And these circRNA-miRNA-mRNA regulatory networks may play an important role in the pathological mechanism of vitiligo. For instance, hsa-miR-149-5p targets genes SEMA4D (ENSG00000187764) and ANKR6 (ENSG00000135299) are involved in regulating melanocyte survival and growth (Soong et al., 2012; Prabhakar et al., 2019). Sem4A4D is a paracrine factor that protects normal human melanocytes to survive under ultraviolet (UV) radiation. Sem4A4D could stimulate cell proliferation and regulates the activity of c-Met receptors, which was determined promotes melanocyte migration (Gotte et al., 2007; Soong et al., 2012). Soong et al. (2012) reported that Sema4D as the ligand for Plexin B1 could suppresses c-Met activation and migration and promotes melanocyte survival and growth. Hsa-miR-320a-3p regulated the target gene SMAD3 (ENSG00000166949). Smad3, a signal mediator of the activin/TGF-beta pathway, which associated with microphthalmia-associated transcription factor (MITF) (Funaba et al., 2003; Webhe et al., 2012). Previous study indicated MITF is a crucial transcription factor expressed in melanocytes (Mizutani et al., 2010; Vachtenheim and Borovansky, 2010; Hu et al., 2020). Hsa-miR-27a-3p targets gene Paxillin (ENSG00000089159). Paxillin, a 69-kDa vinculin binding protein, is significant higher in neonatal melanocytes than in fetal melanocytes (Scott et al., 1995). It indicates that paxillin is closely related to the adhesion ability of melanocytes (Skoczynska et al., 2016).

GO analysis was performed to further annotate the biological functions of the host genes of the differentially expressed circRNAs. Interestingly, the top 20 GO terms of dysregulated circRNAs in vitiligo compared with normal are most enrich in the regulation of primary metabolic process, regulation of cellular metabolic process, negative regulation of cellular metabolic process, primary metabolic process, organic substance metabolic process, cellular metabolic process, organic cyclic compound metabolic process and cellular macromolecule metabolic process (Pietrzak et al., 2012; Atas and Goulen, 2017; Sahoo et al., 2017). This indicates that the dysregulation of circRNAs is closely related to the disorder of the metabolic pathway. In addition, the GO analysis of miRNA also showed that dysregulated miRNAs are closely related to biological or cellular metabolism (Supplementary Figure 1A).

The KEGG pathway of dysregulation of circRNAs mainly enriched in the biological processes such as ubiquitin mediated proteolysis, endocytosis and RNA degradation, and in Jak-STAT signaling pathway. Some studies have indicated that the Jak-STAT signaling pathway is involved in the immune-mediated inflammatory skin diseases such as vitiligo (Chen et al., 2019a; Gomez-Garcia et al., 2019; Montilla et al., 2019; Samaka et al., 2019). Furthermore, through KEGG analysis of miRNAs, some miRNA dysregulated lead to the disorder of certain signaling pathways (Supplementary Figure 1B), such as p53 signaling pathway, mTOR signaling pathway, Insulin signaling pathway and HIF-1 signaling pathway. Studies have shown that p53 signaling pathway and mTOR signaling pathway all played an important role in the synthesis or metabolism of melanin (Kadekaro et al., 2012; Chang et al., 2017; Yang et al., 2018; Li et al., 2019).

We elucidated the circRNA-associated-ceRNA profiles of vitiligo using deep RNA-seq analysis. From the analysis results, we found the circRNA-miRNA-mRNA regulatory network are involved in the regulation of numerous melanocyte functions, further GO and KEGG analysis show that the regulatory functions of these dysregulated circRNAs may closely related to the melanocyte metabolism. Through the analysis of the circRNA-miRNA-mRNA network, we found circ_0087961-miR-27a-3p-PAXILLIN might play an important regulatory role in the pathology of vitiligo. Our study provides a theoretical basis for studying the vitiligo pathogenesis from the perspective of circRNA-miRNA-mRNA network.
The studies involving human participants were reviewed and approved by People’s Hospital of Guangxi Zhuang Autonomous Region. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

LL conceived and wrote the article. LL and ZX designed and performed the research. XQ, TW, MJ, and JQ analyzed the data. CW, RW, and CS contributed essential reagents or tools. All authors read and approved the manuscript.

REFERENCES

Atas, H., and Gonul, M. (2017). Increased risk of metabolic syndrome in patients with vitiligo. Balkan Med. J. 34, 219–225. doi: 10.4274/balkanmedj.2016.1005

Chang, C. H., Kuo, C. J., Ito, T., Su, Y. Y., Jiang, S. T., Chiu, M. H., et al. (2017). CK1alpha ablation in keratinocytes induces p53-dependent, sunburn-sensitive skin hyperpigmentation. Proc. Natl. Acad. Sci. U.S.A. 114, E8035–E8044.

Chen, L. L., and Yang, L. (2015). Regulation of circRNA biogenesis. RNA Biol. 12, 381–388. doi: 10.1080/15476286.2015.1022071

Chen, X., Guo, W., Chang, Y., Chen, J., Kang, P., Yi, X., et al. (2019a). Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8(+) T cells activation via JAK-STAT pathway in vitiligo. Free Radic. Biol. Med. 139, 80–91. doi:10.1016/j.freeradbiomed.2019.05.011

Chen, X., Yang, T., Wang, W., Xi, W., Zhang, T., Li, Q., et al. (2019b). CircRNAs in immune responses and immune diseases. Theranostics 9, 588–607. doi: 10.7150/thno.29678

Delmas, V., and Larue, L. (2019). Molecular and cellular basis of depigmentation in vitiligo patients. Exp. Dermatol. 28, 662–666. doi: 10.1111/exd.13858

Funaba, M., Ikeda, T., Murakami, M., Ogawa, K., Tsuchida, K., Sugino, H., et al. (2003). Transcriptional activation of mouse mast cell Protease-7 by activin and transforming growth factor-beta is inhibited by microphthalmia-associated transcription factor. J. Biol. Chem. 278, 52032–52041. doi:10.1074/jbc.m306991200

Gao, Y., Wang, J., and Zhao, F. (2015). CIRI: an efficient and unbiased algorithm for de novo circular RNA identification. Genome Biol. 16.4.

Gao, Y., Zhang, J., and Zhao, F. (2018). Circular RNA identification based on multiple seed matching. Brief. Bioinform. 19, 803–810. doi: 10.1093/bib/bbx014

Gomez-Garcia, F., Gomez-Arias, P. J., Hernandez, J., Montilla, A. M., Gay-Mimbrera, J., Aguilar-Luque, M., et al. (2019). Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review. BMJ Open 9:028303. doi: 10.1136/bmjopen-2018-028303

Gotte, M., Kersting, C., Radke, I., Kiesel, L., and Wulfing, P. (2017). An expression signature of syndecan-1 (CD138), E-cadherin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res. 9:R8.

Hu, M., Chen, C., Liu, J., Cai, L., Shao, J., Chen, Z., et al. (2020). The melanogenic effects and underlying mechanism of paeoniflorin in human melanocytes and vitiligo mice. Fitoterapia 140:104416. doi:10.1016/j.fitote.2019.104416

Iannella, G., Greco, A., Didona, D., Didona, B., Granata, G., Manno, A., et al. (2016). Vitiligo: pathogenesis, clinical variants and treatment approaches. Autoimmun. Rev. 15, 335–343. doi: 10.1016/j.autrev.2015.12.006

Kadekar, A. L., Chen, J., Yang, J., Chen, S., Jameson, J., Swope, V. B., et al. (2012). Alpha-melanocyte-stimulating hormone suppresses oxidative stress through a p53-mediated signaling pathway in human melanocytes. Mol. Cancer Res. 10, 778–786. doi: 10.1158/1541-7786.mcr-11-0436

Kristensen, L. S., Andersen, M. S., Stagsted, I. V. W., Ebbesen, K. K., Hansen, T. B., and Kjems, J. (2019). The biogenesis, biology and characterization of circular RNAs. Nat. Rev. Genet. 20, 675–691.

Langmead, B., Trapnell, C., Pop, M., and Salzberg, S. L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10:R25.

Lei, K., Bai, H., Wei, Z., Xie, C., Wang, J., Li, J., et al. (2018). The mechanism and function of circular RNAs in human diseases. Exp. Cell Res. 368, 147–158. doi: 10.1016/j.yexcr.2018.05.002

Li, C., Chen, H., Lan, Z., He, S., Chen, R., Wang, F., et al. (2019). miTOR-dependent upregulation of xCT blocks melanin synthesis and promotes tumorigenesis. Cell Death Differ. 26, 2015–2028. doi:10.1038/s41418-019-0274-0

Liu, C.-X., Li, X., Nan, F., Jiang, S., Gao, X., Guo, S. K., et al. (2019). Structure and degradation of circular RNAs regulate PKR activation in innate immunity. Cell 177, 865.e21–880.e21.

Malhotra, N., and Dytoc, M. (2013). The pathogenesis of vitiligo. J. Cutan. Med. Surg. 17, 153–172.

Mansuri, M. S., Singh, M., and Begum, R. (2016). miRNA signatures and transcriptional regulation of their target genes in vitiligo. J. Dermatol. Sci. 84, 50–58. doi:10.1016/j.jdermsci.2016.07.003

McCmack, S., Jens, M., Elefshiniot, A., Torti, F., Krueger, J., Rybak, A., et al. (2013). Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 495, 333–338. doi: 10.1038/nature11928

Mizutani, Y., Hayashi, N., Kawashima, M., and Imokawa, G. (2010). A single UVB exposure increases the expression of functional KIT in human melanocytes by up-regulating MITF expression through the phosphorylation of p38/CREB. Arch. Dermatol. Res. 302, 283–294. doi:10.1007/s00403-009-1007-x

Montilla, A. M., Gomez-Garcia, F., Gomez-Arias, P. J., Gay-Mimbrera, J., Hernandez-Parada, J., Isla-Tejera, B., et al. (2019). Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol. Therapy 9, 655–683. doi: 10.1007/s13555-019-00329-y

Pertea, M., Kim, D., Pertea, G. M., Leek, J. T., and Salzberg, S. L. (2016). Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat. Protoc. 11, 1650–1677. doi:10.1038/nprot.2016.095

Pietrzak, A., Bartosinska, J., Hercogova, J., Lotti, T. M., and Chodorowska, G. (2012). Metabolic syndrome in vitiligo. Dermatol. Therapy 25(1), S41–S43.

Prabhakar, K., Rodriotague, C. L., Jayanth, A. S., Mikhel, D. M., Bhasker, A. L., Perera, R. J., et al. (2019). Role of miR-214 in regulation of beta-catenin and
the malignant phenotype of melanoma. *Mol. Carcinogenesis.* 58, 1974–1984. doi: 10.1002/mc.23089

Sahoo, A., Lee, B., Boniface, K., Seneschal, J., Sahoo, S. K., Seki, T., et al. (2017). MicroRNA-211 regulates oxidative phosphorylation and energy metabolism in human vitiligo. *J. Invest. Dermatol.* 137, 1965–1974. doi: 10.1016/j.jid.2017.04.025

Salzman, J. (2016). Circular RNA expression: its potential regulation and function. *Trends Genet.* 32, 309–316. doi: 10.1016/j.tig.2016.03.002

Samaka, R. M., Basha, M. A., and Menesy, D. (2019). Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo. *Clin. Cosmet. Investig. Dermatol.* 12, 469–480. doi: 10.2147/ccid.s210106

Scott, G. A., Liang, H., and Cassidy, L. L. (1995). Developmental regulation of focal contact protein expression in human melanocytes. *Pigment Cell Res.* 8, 221–228. doi: 10.1111/j.1600-0749.1995.tb00667.x

Sharma, C. K., Sharma, M., and Prasad, K. (2017). Involvement of different genes expressions during immunological and inflammatory responses in vitiligo. *Crit. Rev. Eukaryot. Gene Exp.* 27, 277–287. doi: 10.1615/critrevueukaryotgeneexpr.2017019558

Skoczynska, A., Budzisz, E., Podgorna, K., and Rotsztejn, H. (2016). Paxillin and its role in the aging process of skin cells. *Postepy Hig. Med. Dosw.* 70, 1087–1094. doi: 10.5604/17322693.1221385

Soong, J., Chen, Y., Shustef, E. M., and Scott, G. A. (2012). Sema4D, the ligand for Plexin B1, suppresses c-Met activation and migration and promotes melanocyte survival and growth. *J. Investig. Dermatol.* 132, 1230–1238. doi: 10.1038/jid.2011.414

Speckknaert, R., and van Geel, N. (2017). Vitiligo: an update on pathophysiology and treatment options. *Am. J. Clin. Dermatol.* 18, 733–744. doi: 10.1007/s40257-017-0298-5

Vachtenheim, J., and Borovansky, J. (2010). “Transcription physiology” of pigment formation in melanocytes: central role of MITF. *Exp. Dermatol.* 19, 617–627. doi: 10.1111/j.1600-0625.2009.01053.x

Vaish, U., Kumar, A. A., Varshney, S., Ghosh, S., Sengupta, S., Sood, C., et al. (2019). Micro RNAs upregulated in Vitiligo skin play an important role in its aetio-pathogenesis by altering TRP1 expression and keratinocyte-melanocytes cross-talk. *Sci. Rep.* 9:10079.

Wehbe, M., Soudja, S. M., Mas, A., Chasson, L., Guinamard, R., de Tenobsche, C. P., et al. (2012). Epithelial-mesenchymal-transition-like and TGFbeta pathways associated with autochthonous inflammatory melanoma development in mice. *PLoS One* 7:e49419. doi: 10.1371/journal.pone.0049419

Yang, Z., Zeng, B., Pan, Y., Huang, P., and Wang, C. (2018). Autophagy participates in isoliquiritigenin-induced melanin degradation in human epidermal keratinocytes through PI3K/AKT/mTOR signaling. *Biomed. Pharmacother.* 97, 248–254. doi: 10.1016/j.biopha.2017.10.070

Yuan, X., Meng, D., Cao, P., Sun, L., Pang, Y., Li, Y., et al. (2019). Identification of pathogenic genes and transcription factors in vitiligo. *Dermatol. Therapy* 32:e13025

Zhong, S., Zhou, S., Yang, S., Yu, X., Xu, H., Wang, J., et al. (2019). Identification of internal control genes for circular RNAs. *Biotechnol. Lett.* 41, 1111–1119. doi: 10.1007/s10529-019-02723-0

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Li, Xia, Qian, Wang, Jiang, Qin, Wang, Wu and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.